Skip to content

Infectious diseases and microbiome

Infectious diseases and microbiome

Multi-omics characterization of pathogens, host response and microbial ecosystems.

8
analyses
4
questions
1
program

Programs

Our programs

Xplorer™ program

Microbiome Xplorer™

How a treatment, a diet or a product reshapes a microbial community, and how the host responds.

  • 16S and shotgun metagenomics
  • Metatranscriptomics and metabolomics on site
  • Host markers on the same samples
4
layers measured
4
questions
7
application areas

Questions

Host and community, from one collection

Four angles on the same samples: the pathogen, the community, the host and the clinical context.

The pathogen

Pathogen genomics

Strains, lineages and resistance-associated variants, followed across timepoints as the population changes under treatment pressure.

  • Strains and lineagesWGS · targeted
  • Antimicrobial resistanceshotgun · targeted
  • Treatment pressureacross timepoints

The community

Microbiome profiling

Composition, diversity and differential abundance, with functional potential and strain-level resolution where the question needs them.

  • Composition and diversity16S
  • Function and strainsshotgun
  • Sequencing depthset by the question

The host

Host response

Transcriptional changes associated with infection, severity, progression or treatment response, read at gene and pathway level.

  • Host transcriptomebulk RNA-seq
  • Host and pathogen togethermetatranscriptomics
  • ProteinsMS

Together

Clinical context and signatures

Molecular measurements set against severity, treatment, timepoint and outcome, so a signal of infection is not mistaken for how sick the patient already was.

  • Clinical integrationseverity · outcome
  • Signature discoveryindependent cohorts
  • Reportingversions · QC · matrices

Your study

How a study runs

  1. 01

    Question and design

    Which communities change, which functions they carry and how the host responds, measured on one collection, with sequencing depth set by the question and the sample complexity.

  2. 02

    Samples

    Swabs, stool, biopsies, blood, isolates, biofilms and environmental samples.

  3. 03

    Laboratory measurement

    Host transcriptome, 16S and shotgun metagenomics, from matrices where a standard extraction underperforms.

  4. 04

    Interpretation

    Interpretation written against the question the study started from.

  5. 05

    Deliverables

    A QC report for every sample, and turnaround published per service.

What the analysis covers

Eight layers, read on the same samples

Pathogen genomics
Whole-genome and targeted sequencing for strain and lineage characterization, variant profiling, phylogenetic relationships and resistance-associated variants. Across timepoints, the same framework tracks how a pathogen population changes under treatment pressure.
Microbiome profiling
16S for community composition, diversity and differential abundance. Shotgun metagenomics where the question needs functional potential, strain-level resolution or low-abundance populations. Sequencing depth is set by the question and the sample complexity, not by a default.
Antimicrobial resistance
Resistance determinants identified from shotgun data and, where a specific marker matters, monitored by targeted assays across the cohort.
Host response
Bulk RNA-seq for the transcriptional changes associated with infection, severity, progression or treatment response, with differential expression reported at gene and pathway level.
Host and pathogen together
Metatranscriptomics, where both responses have to be read from the same material, so the pathogen’s activity and the host’s reaction are measured on one sample rather than inferred from two.
Proteomics
Protein-level quantification by mass spectrometry, matched against the transcriptomic result. Transcript and protein levels diverge often enough that agreement between them is informative in itself.
Integration with clinical context
Molecular measurements set against severity, treatment, sampling timepoint, outcome and patient characteristics, which is what separates a signal associated with infection from one associated with how sick the patient already was.
Signature discovery
Molecular signatures associated with severity, progression, treatment response or failure. Where independent cohorts exist, candidates are tested on data that did not contribute to finding them.

What you receive

An integrated report

Laboratory
A QC report for every sample. Demultiplexed FASTQ with run-level QC metrics for the sequencing services. Result tables for PCR work. Turnaround published per service.
Report
Tool versions, parameters, filtering criteria and statistical thresholds for every step. QC per sample and per cohort, with exclusions stated and justified. Interpretation written against the question the study started from.
Data package
Processed matrices, result tables, versioned pipelines and figures, delivered for review or reproduction by a third party.

Practical terms

Report
PDF with a verifiable, time-stamped fingerprint
Data
Data is hosted in the EU, with backups in France, a separate space per team
Confidentiality
Mutual NDA available before any detail is shared, at no charge
AI
Models on our servers, no data sent to an external AI
Turnaround
In working days, confirmed in the quote, from GO

Sample requirements

These are the matrices where a standard extraction underperforms, so the protocol is chosen per matrix rather than applied as one blanket standard. Collection protocols are published per sample type, and the DNA criteria apply after extraction.

Biosafety and containment

Sample logistics and laboratory handling are scoped to your biosafety and containment requirements at intake, before anything is shipped. Part of our laboratories sit within the Méditerranée Infection building in Marseille.

Where the bench stops

A platform order delivers primary data. Alignment, quantification, integration, biomarker discovery and modeling are run by our computational team within Microbiome Xplorer™: ask for it in the quote request and both are scoped together.

A project in this field?

Tell us the pathogen, the cohort and the question.